
BioKier, a US-based pharmaceutical firm, innovates drugs for diabetes and related disorders.
BioKier, founded in Chapel Hill, United States, is an early-stage pharmaceutical company focused on developing innovative drugs for diabetes and related disorders. The company's core mission is to improve the quality of life for individuals with diabetes through groundbreaking therapeutic solutions. BioKier's primary product, BKR-017, is designed to address type 2 diabetes, with ongoing clinical studies demonstrating its potential efficacy. The firm aims to revolutionize diabetes treatment and expand its market reach within the pharmaceutical industry.
Notable figures associated with BioKier include a team of experienced management and advisors who bring extensive expertise in pharmaceutical development and diabetes research. The company has achieved significant milestones, including the completion of a 12-week clinical study and a 4-week study of BKR-017 in type 2 diabetes patients, showcasing promising results. BioKier's innovative approach and successful clinical trials underscore its potential impact on diabetes treatment, positioning it as a key player in the healthcare sector.

EIR Pharmaceuticals

Kira Pharmaceuticals
kirapharma.com

BioQ Pharma
bioqpharma.com

JK BioPharma Solutions

KeifeRx
keiferx.com

Know Bio
knowbiollc.com

K2bio
k2-biolabs.com

BioHealthonomics

Kiniksa Pharmaceuticals
kiniksa.com

Curie.Bio
curie.bio

Kirax

Bionpharma
bionpharma.com

Kathera Bioscience
katherabio.com

Kinnear Pharmaceuticals
kinnearpharma.com

Bayer Pharmaceuticals
bayer.com
Companies similar to BioKier include EIR Pharmaceuticals, Kira Pharmaceuticals, BioQ Pharma and JK BioPharma Solutions.
BioKier was founded in 2008.
BioKier's headquarters is located in Chapel Hill, NC, US.
BioKier's most recent funding round was for $150k (USD) in January 2015.
As of Jan 1, 2015, BioKier has raised a total of $2.9M (USD).
BioKier has 5 employees as of Feb 5, 2024.